Triacylglycerol and phospholipid hydrolysis in human plasma lipoproteins: role of lipoprotein and hepatic lipase.
To explore the interactions of triacylglycerol and phospholipid hydrolysis in lipoprotein conversions and remodeling, we compared the activities of lipoprotein and hepatic lipases on human VLDL, IDL, LDL, and HDL2. Triacylglycerol and phospholipid hydrolysis by each enzyme were measured concomitantly in each lipoprotein class by measuring hydrolysis of [14C]triolein and [3H]dipalmitoylphosphatidylcholine incorporated into each lipoprotein by lipid transfer processes. Hepatic lipase was 2-3 times more efficient than lipoprotein lipase at hydrolyzing phospholipid both in absolute terms and in relation to triacylglycerol hydrolysis in all lipoproteins. The relationship between phospholipid hydrolysis and triacylglycerol hydrolysis was generally linear until half of particle triacylglycerol was hydrolyzed. For either enzyme acting on a single lipoprotein fraction, the degree of phosphohydrolysis closely correlated with triacylglycerol hydrolysis and was largely independent of the kinetics of hydrolysis, suggesting that triacylglycerol removed from a lipoprotein core is an important determinant of phospholipid removal via hydrolysis by the lipase. Phospholipid hydrolysis relative to triacylglycerol hydrolysis was most efficient in VLDL followed in descending order by IDL, HDL, and LDL. Even with hepatic lipase, phospholipid hydrolysis could not deplete VLDL and IDL of sufficient phospholipid molecules to account for the loss of surface phospholipid that accompanies triacylglycerol hydrolysis and decreasing core volume as LDL is formed (or for conversion of HDL2 to HDL3). Thus, shedding of whole phospholipid molecules, presumably in liposomal-like particles, must be a major mechanism for losing excess surface lipid as large lipoprotein particles are converted to smaller particles. Also, this shedding phenomenon, like phospholipid hydrolysis, is closely related to the hydrolysis of lipoprotein triacylglycerol.
Deckelbaum
R J
RJ
Department of Pediatrics, Columbia University, New York, New York 10032.
Ramakrishnan
R
R
Eisenberg
S
S
Olivecrona
T
T
Bengtsson-Olivecrona
G
G
D015060:1,2-Dipalmitoylphosphatidylcholine / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D008049:Lipase / Q000378:metabolism*; D008071:Lipoprotein Lipase / Q000378:metabolism; D008074:Lipoproteins / Q000097:blood / Q000737:chemistry / Q000378:metabolism*; D053419:Lipoproteins, IDL; D008077:Lipoproteins, LDL / Q000097:blood / Q000737:chemistry / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000097:blood / Q000737:chemistry / Q000378:metabolism; D008099:Liver / Q000201:enzymology*; D010743:Phospholipids / Q000378:metabolism*; D014280:Triglycerides / Q000378:metabolism*; D014304:Triolein / Q000378:metabolism
D008074:Lipoproteins; D053419:Lipoproteins, IDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D014280:Triglycerides; D014304:Triolein; D015060:1,2-Dipalmitoylphosphatidylcholine; D008049:Lipase; D008071:Lipoprotein Lipase